What Is Neuropathic Pain?

Neuropathic pain is a chronic pain condition arising from a lesion or disease directly affecting the somatosensory nervous system, rather than from tissue damage activating normal pain receptors. It is distinguished from nociceptive pain, which serves a protective warning function, by its persistence after the original injury has healed and by characteristic symptoms including spontaneous burning or shooting pain, allodynia (pain from stimuli that do not normally cause pain), and hyperalgesia (an exaggerated response to genuinely painful stimuli). Neuropathic pain affects an estimated 7 to 10 percent of the general population and represents one of the most difficult chronic pain conditions to treat.

The condition can follow peripheral nerve damage from diabetes, viral infections such as herpes zoster, traumatic injury, or chemotherapy, as well as central nervous system lesions from stroke, multiple sclerosis, or spinal cord injury. Understanding and treating neuropathic pain requires integrating neurophysiology, pharmacology, and biomedical engineering approaches.

Mechanisms of Neuropathic Pain

At the cellular level, neuropathic pain involves maladaptive plasticity in both peripheral and central neurons. Peripheral sensitization occurs when injured or inflamed sensory neurons develop abnormal spontaneous discharge, reduced firing thresholds, and ectopic activity originating from the neuroma or dorsal root ganglion rather than from the peripheral receptive field. Changes in sodium channel subtype expression, particularly an upregulation of Nav1.3, contribute to this hyperexcitability. Central sensitization refers to increased synaptic gain in dorsal horn neurons of the spinal cord, driven by glutamate acting on NMDA receptors, which amplifies and prolongs the response to incoming sensory signals. Descending modulatory pathways from the brainstem, which normally suppress pain transmission, are also disrupted in neuropathic states. Research on recent progress and challenges in spinal cord injury treatment addresses how spinal cord lesions produce both the motor and sensory abnormalities characteristic of central neuropathic pain.

Diagnosis and Assessment

The diagnosis of neuropathic pain relies on a combination of clinical history, bedside sensory examination, and quantitative sensory testing (QST). QST systematically evaluates thermal and mechanical detection thresholds as well as pain thresholds using standardized stimuli, allowing researchers to characterize the specific sensory profile of an individual patient's neuropathy. Nerve conduction studies and skin punch biopsy with measurement of intraepidermal nerve fiber density provide objective evidence of peripheral nerve damage. Patient-reported outcome instruments, including the Neuropathic Pain Symptom Inventory (NPSI) and the DN4 questionnaire, quantify symptom intensity and quality in a format suitable for clinical trials. Functional neuroimaging has identified altered activity in the thalamus, anterior cingulate cortex, and prefrontal regions that correlates with pain intensity and contributes to the emotional and cognitive dimensions of the experience. A PMC review of neurophysiology and neural engineering discusses how electrophysiological methods can provide objective biomarkers complementing subjective pain assessment tools.

Treatment Approaches

Pharmacological treatment of neuropathic pain relies on agents that target aberrant peripheral and central sensitization mechanisms rather than prostaglandin-mediated inflammation. First-line options include gabapentinoids (gabapentin and pregabalin), which block voltage-gated calcium channel alpha-2-delta subunits and reduce central sensitization, and tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors that strengthen descending inhibitory pathways. Topical lidocaine patches and capsaicin 8% patches reduce peripheral input. When pharmacotherapy is insufficient, interventional strategies include spinal cord stimulation (SCS), which delivers epidural electrical pulses to the dorsal columns and suppresses pain transmission in the spinal cord, and dorsal root ganglion stimulation, which targets the cell bodies of sensory neurons with greater anatomical specificity. A NSF-DFG workshop report on neurotechnologies identifies closed-loop neurostimulation as a direction for improving the selectivity and efficacy of SCS for neuropathic pain.

Applications

Neuropathic pain research has applications in a range of fields, including:

• Implantable spinal cord and peripheral nerve stimulation devices for chronic pain management
• Wearable pain monitoring systems using biosensors and machine learning for objective assessment
• Drug delivery systems providing targeted intrathecal analgesic infusion
• In-vitro and organoid models of peripheral neuropathy for pharmaceutical screening
• Biomarker discovery platforms for patient stratification in clinical trials